One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment

Table 3 Long-term sequelae and SGRQ score of severe COVID-19 patients were followed at 3 months and 1 year

Syndrome	Total patients (n = 25)			hUC-MSC (n = 8)			Control (n = 17)			1-year follow-up
Syndrome	3 Months	1 Year	P value^#	3 Months	1 Year	P value^#	3 Months	1 Year	P value^#	Control	hUC-MSC	P value^##
Fatigue	17(68.0%)	15(60.0%)	0.769	4(50.0%)	2(25.0%)	0.608	13(76.5%)	13(76.5%)	1.000	13(76.5%)	2(25.0%)	0.028*
Short of breath	19(76.0%)	7(28.0%)	0.002**	6(75.0%)	1(12.5%)	0.041*	13(76.5%)	6(35.3%)	0.037*	6(35.3%)	1(12.5%)	0.362
Sleep disorders	16(64.0%)	12(48.0%)	0.393	5(62.5%)	3(37.5%)	0.619	11(64.7%)	9(52.9%)	0.728	9(52.9%)	3(37.5%)	0.642
Cough	9(36.0%)	3(12.0%)	0.095	3(37.5%)	1(12.5%)	0.569	6(35.3%)	2(11.8%)	0.225	2(11.8%)	1(12.5%)	1.000
SGRQ (Mean ± SD)	26.76 ± 11.34	12.32 ± 8.88	0.000***	15.25 ± 3.69	9.13 ± 7.47	0.012*	32.18 ± 9.46	13.82 ± 9.29	0.000***	13.82 ± 9.29	9.13 ± 7.47	0.224

hUC-MSCs human umbilical cord mesenchymal stem cells, SGRQ St George’s Respiratory Questionnaire, ^# 3 months compared with 1 year, ^## hUC-MSCs group compared with control group
*P < 0.05; ** P < 0.01; ***P < 0.001

ISSN: 1757-6512